Mizagliflozin is under clinical development by Vogenx and currently in Phase II for Hypoglycemia. According to GlobalData, Phase II drugs for Hypoglycemia have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mizagliflozin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mizagliflozin is under development for the treatment of postbariatric hypoglycemia (PBH). It is administered through oral route in the form of liquid or encapsulated formulation. The drug candidate acts by targeting selective inhibitor of sodium dependent glucose cotransporter 1 (SGLT1).
Vogenx is focused on developing novel therapeutics to address unmet medical need of patients suffering from rare disease. Vogenx is headquartered in Durham, North Carolina, the US.
For a complete picture of Mizagliflozin’s drug-specific PTSR and LoA scores, buy the report here.